CytomX Therapeutics, Inc. (CTMX): R&D Expense
$68.73M
Year ended 2025-12-31
$73.38M
Trailing 12 months to 2026-06-30
-14.9%
3-year compound annual growth
-9.5%
5-year compound annual growth
+9.3%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $68.73M | -17.6% | 2026-03-16, From 2025-01-01 |
| 2024-12-31 | $83.38M | +7.3% | 2026-03-16, From 2024-01-01 |
| 2023-12-31 | $77.68M | -30.4% | 2025-03-06, From 2023-01-01 |
| 2022-12-31 | $111.65M | -2.2% | 2024-03-11, From 2022-01-01 |
| 2021-12-31 | $114.19M | +1.1% | 2023-03-27, From 2021-01-01 |
| 2020-12-31 | $112.94M | -14.2% | 2023-03-27, From 2020-01-01 |
| 2019-12-31 | $131.62M | +26.7% | 2023-03-27, From 2019-01-01 |
| 2018-12-31 | $103.87M | +12.6% | 2021-02-24, From 2018-01-01 |
| 2017-12-31 | $92.28M | +68.5% | 2020-02-27, From 2017-01-01 |
| 2016-12-31 | $54.76M | +93.1% | 2019-02-27, From 2016-01-01 |
| 2015-12-31 | $28.36M | +0.2% | 2018-03-07, From 2015-01-01 |
| 2014-12-31 | $28.30M | +159.9% | 2017-03-02, From 2014-01-01 |
| 2013-12-31 | $10.89M | n/a | 2016-03-07, From 2013-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | $68.73M | -17.6% |
| AbCellera Biologics Inc. (ABCL) | 2025-12-31 | $186.83M | +11.7% |
| Eton Pharmaceuticals, Inc. (ETON) | 2025-12-31 | $7.76M | +138.6% |
| Bicycle Therapeutics PLC (BCYC) | 2025-12-31 | $240.28M | +38.9% |
| Assembly Biosciences, Inc. (ASMB) | 2025-12-31 | $64.81M | +15.9% |
| ADC Therapeutics SA (ADCT) | 2025-12-31 | $104.00M | -5.1% |
| Viridian Therapeutics, Inc. (VRDN) | 2025-12-31 | $338.93M | +42.3% |
| Arcturus Therapeutics Holdings Inc. (ARCT) | 2025-12-31 | $112.21M | -42.5% |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $0 | -100.0% |
Compare CTMX, ABCL, ETON, BCYC side by side · Screen every company in Pharmaceutical Preparations ↗